Uric Acid as a Potential Cue to Screen for Iron Overload

References

1. ↵
   McLaren GD, McLaren CE, Adams PC, et al. Hemochromatosis and Iron Overload Screen (HEIRS) Study Research Investigators. Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. Can J Gastroenterol 2008; 22: 923–30.

   OpenUrlPubMedWeb of Science
2. ↵
   Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358: 221–30.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   Centers for Disease Control and Prevention. Hemochromatosis: (Iron Storage Disease), Facts, NCBDDD 6/1/2011. http://www.cdc.gov/ncbddd/hemochromatosis/facts.html.
4. ↵
   Waalen J, Felitti VJ, Beutler E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood 2008; 111: 3373–6.

   OpenUrlAbstract/FREE Full Text
5. ↵
   US Preventive Services Task Force. Screening for hemochromatosis: recommendation statement. Ann Intern Med 2006; 145: 204–8.

   OpenUrlPubMedWeb of Science
6. ↵
   Phatak PD, Bonkovsky HL, Kowdley KV. Hereditary hemochromatosis: time for targeted screening. Ann Intern Med 2008; 149: 270–2.

   OpenUrlCrossRefPubMed
7. ↵
   American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care 2010; 33: S11–S61.

   OpenUrlFREE Full Text
8. ↵
   Cooper RJ, Hoffman JR, Bartlett JG, et al. Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Intern Med 2001; 134: 509–17.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   Merriman TR, Dalbeth N. The genetic basis of hyperuricaemia and gout. Joint Bone Spine 2011; 78: 35–40.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    Schumacher HR, Taylor W, Edwards L, et al. Outcome domains for studies of acute and chronic gout. J Rheumatol 2009; 36: 2342–5.

    OpenUrlAbstract/FREE Full Text
11. ↵
    Weaver AL. Epidemiology of gout. Clev Clin J Med 2008; 75(Suppl 5): S9–S12.

    OpenUrlAbstract/FREE Full Text
12. ↵
    Xu C, Yu C, Xu L, Miao M, Li Y. High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study. PLoS One. 2010; 5(7): e11578.

    OpenUrlCrossRefPubMed
13. ↵
    Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183–90.

    OpenUrlAbstract/FREE Full Text
14. ↵
    Ghio AJ, Ford ES, Kennedy TP, Hoidal JR. The association between serum ferritin and uric acid in humans. Free Radic Res 2005; 39: 337–42.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    National Center for Health Statistics, Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. Available at: http://www.cdc.gov/nchs/nhanes.htm. Accessed 4 August 2010.
16. ↵
    Addison G, Beamish M, Hales C, et al. An immunoradiometric assay for ferritin in the serum of normal patients and patients with iron deficiency and iron overload. J Clin Path 1972; 25: 326.

    OpenUrlAbstract/FREE Full Text
17. ↵
    Miles L. Measurement of serum ferritin by a 2-site immunoradiometric assay. In: Abraham G, ed. Handbook of radioimmunoassay. New York: Marcel Dekker, Inc., 1977; 131–177.
18. ↵
    Centers for Disease Control and Prevention. Hemochromatosis (iron storage disease): training & education - treatment & management. Monitoring treatment. Available at: http://www.cdc.gov/ncbddd/hemochromatosis/training/treatment/monitoring_treatment.html. Accessed 30 December 2010.
19. ↵
    Iron Disorders Institute. Iron tests. Available at: http://www.irondisorders.org/iron-tests/. Accessed 30 December 2010.
20. ↵
    Schlesinger N. Diagnosis of gout: clinical, laboratory, and radiologic findings. Am J Manag Care 2005; 11: S443–50.

    OpenUrlPubMedWeb of Science
21. ↵
    Pascual-Figal DA, Hurtado-Martínez JA, Redondo B, Antolinos MJ, Ruiperez JA, Valdes M. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail 2007; 9(5): 518–24.

    OpenUrlCrossRefPubMed
22. ↵
    Morrison ED, Brandhagen DJ, Phatak PD, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003; 138: 627–33.

    OpenUrlPubMedWeb of Science
23. ↵
    Afzali A, Weiss NS, Boyko EJ, Ioannou GN. Association between serum uric acid level and chronic liver disease in the United States. Hepatology 2010; 52: 578–89.

    OpenUrlCrossRefPubMedWeb of Science
24. ↵
    National Center for Health Statistics, Centers for Disease Control and Prevention. NHANES 1999–2000 data documentation. Revised August 2006. Laboratory 18–biochemistry profile. Available at: http://www.cdc.gov/nchs/data/nhanes/nhanes_99_00/lab18_doc.pdf. Accessed 18 May 2011.
25. ↵
    Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888–97.

    OpenUrlAbstract/FREE Full Text
26. ↵
    Paller MS. Hemoglobin- and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity. Am J Physiol 1988; 255: F539–44.

    OpenUrlPubMedWeb of Science
27. ↵
    Alfrey AC, Froment DH, Hammond WS. Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis. Kidney Int 1989; 36: 753–9.

    OpenUrlCrossRefPubMed
28. ↵
    Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78: 6858–62.

    OpenUrlAbstract/FREE Full Text
29. ↵
    Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41(6): 1183–90.

    OpenUrlAbstract/FREE Full Text
30. ↵
    Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000; 148(1): 131–9.

    OpenUrlCrossRefPubMedWeb of Science
31. ↵
    Sudman S, Warnecke R, Johnson T, O’Rourke D, Davis AM. Cognitive aspects of reporting cancer prevention examination and texts. Vital Health Stat 6. 1994; 7: 1–171.

    OpenUrl